SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,432.87 |
Enterprise Value ($M) | 1,264.23 |
Book Value ($M) | 382.67 |
Book Value / Share | 20.53 |
Price / Book | 3.74 |
NCAV ($M) | 380.60 |
NCAV / Share | 20.42 |
Price / NCAV | 3.76 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.39 |
Return on Assets (ROA) | -1.42 |
Return on Equity (ROE) | -1.74 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 13.59 |
Current Ratio | 13.59 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 414.19 |
Assets | 416.26 |
Liabilities | 33.59 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
58,006 | 508,702 | 11.40 | |
36,591 | 252,313 | 14.50 | |
50,302 | 358,316 | 14.04 | |
30,653 | 240,136 | 12.76 | |
37,848 | 518,753 | 7.30 | |
(click for more detail) |
Similar Companies | |
---|---|
PHVS – Pharvaris N.V. | PLRX – Pliant Therapeutics, Inc. |
PMVP – PMV Pharmaceuticals, Inc. | PRLD – Prelude Therapeutics Incorporated |
PRTA – Prothena Corporation plc |
Financial data and stock pages provided by
Fintel.io